New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.
30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
